Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or philadelphia-positive acute lymphoblastic leukemia

Acta Haematologica

Volumn 122, Issue 1, 2009, Pages 6-10

  Klyuchnikov, Evgeny ^a,b   Schafhausen, Philippe ^a   Kröger, Nicolaus ^a   Brummendorf, Tim H ^a   Osanmaz, Okay ^a   Asenova, Svetlana ^a   Zabelina, Tatjana ^a   Ocheni, Sunday ^a,c   Ayuk, Francis ^a   Zander, Axel R ^a   Bacher, Ulrike ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c University of Enugu   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BCR ABL PROTEIN; BOSUTINIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HYDROXYUREA; IDARUBICIN; IMATINIB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MINIMAL RESIDUAL DISEASE; MYELOABLATIVE CONDITIONING; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; WHOLE BODY RADIATION;

AGED; ANILINE COMPOUNDS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NITRILES; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINOLINES; STEM CELL TRANSPLANTATION; THIAZOLES;

EID: 67650119418     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228587     Document Type: Article

References (25)

1. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D: Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521.
2. De Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Rea D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, Macintyre E, Lheritier V, Vernant JP, Thomas X, Ifrah N, Dombret H: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109: 1408-1413. (Pubitemid 46239571)
3. Bartolovic K, Balabanov S, Hartmann U, Komor M, Boehmler AM, Buhring HJ, Mohle R, Hoelzer D, Kanz L, Hofmann WK, Brummendorf TH: Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004; 103: 523-529.
4. Balabanov S, Appel S, Kanz L, Brossart P, Brummendorf TH: Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells. Ann NY Acad Sci 2005; 1044: 168-177.
5. Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, de LM, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M: Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590-1595. (Pubitemid 34925133)
6. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP, Lennard AL, Pallan L, Arrazi JM, Perz JB, O'Shea D, Goldman JM, Apperley JF, Craddock CF: Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614-4617.
7. DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ: Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004; 10: 5065-5071.
8. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ, Appelbaum FR, Radich JP: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791-2793.
9. Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R: Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia- positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 2008; 33: 174-177.
10. Reddiconto G, Chiusolo P, Fiorini A, Farina G, Sora F, Leone G, Sica S: Dasatinib restores full donor chimerism in a patient with imatinib- resistant Ph+ ALL relapsing after unrelated cord blood transplantation. Leuk Lymphoma 2007; 48: 2054-2057.
11. Atallah E, Kantarjian H, De Lima M, Borthakur G, Wierda W, Champlin R, Cortes J: The role of dasatinib in patients with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT). ASH annual meeting abstract. Blood 2006; 108: 4520.
12. Ocheni S, Iwanski GB, Schafhausen P, Zander AR, Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brummendorf TH, Kroger N, Bacher U: Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma 2009; 50: 551-558.
13. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ: Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
14. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.
15. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473-481.
16. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R: Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9189.
17. Ramirez P, Dipersio JF: Therapy options in imatinib failures. Oncologist 2008; 13: 424-434.
18. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M: Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109: 4143-4150. (Pubitemid 46743375)
19. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207-3213. (Pubitemid 46572505)
20. Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, Knobl P, Haas OA, Thalhammer R, Schwarzinger I, Sillaber C, Jager U, Valent P: Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest 2007; 37: 808-813.
21. Altintas A, Cil T, Kilinc I, Kaplan MA, Ayyildiz O: Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. J Neurooncol 2007; 84: 103-105.
22. Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S: Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosomepositive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002; 119: 106-108.
23. Abruzzese E, Del PG, Barbato R, Fratoni S, Trawinska MM, Zangrilli D, Coletta AM, Patroi IM, Francesconi F, Santeusanio G, De FP, Amadori S: Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825. Blood 2006; 107: 4571-4572.
24. Breccia M, Nanni M, Mancini F, Russo E, Mecarocci S, Alimena G: Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. Haematologica 2004; 89:e35-e36.
25. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth- Hansen H, Hoglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY: Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008; 112: 1005-1012.